"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 3 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 07; 72(7):1067-1071.
-
Sayej WN, Isakoff MS, DiGiuseppe JA, Moote D, Balarezo F, Finck C, Hyams JS. Primary Cutaneous Follicle Center Lymphoma in a 16-Year-old boy With Crohn Disease Exposed to Infliximab and Methotrexate. J Pediatr Gastroenterol Nutr. 2020 02; 70(2):e49-e50.
-
Sands BE, Schreiber S, Lirio RA. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply. N Engl J Med. 2020 01 02; 382(1):93-94.
-
Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285.
-
Cohen SB, Kremer JM, Dandreo KJ, Reed GW, Magner R, Shan Y, Kafka S, DeHoratius RJ, Ellis L, Parenti D. Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clin Rheumatol. 2019 Sep; 38(9):2501-2508.
-
Kay J. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. J Intern Med. 2019 06; 285(6):693-695.
-
Kay J, Dörner T, Emery P, Kvien TK, Breedveld FC. Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. Ann Rheum Dis. 2020 04; 79(4):e44.
-
Kay J, Winthrop KL. Pharmacotherapy: Biosimilar switching - "To set a form upon desired change". Nat Rev Rheumatol. 2017 07; 13(7):391-392.
-
Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017 01; 76(1):4-6.
-
Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, Willers J, Kay J. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016 Apr; 54(4):315-22.